Content overview: “U.S. Proposes Rule to Scrutinize Outbound Licensing Deals with Chinese Biotech Firms”. government is preparing to introduce a proposed rule that would add new layers of scrutiny to outbound licensing deals between American companies and Chinese biotech firms. The move is part of a broader effort to protect U.S. intellectual property and national security interests in the life sciences sector. While the exact scope and enforcement mechanisms remain unclear, industry experts anticipate the rule could affect a wide range of collaborations, from early-stage research partnerships to late-stage commercialization agreements.
The proposal is expected to be published in the Federal Register in the coming weeks, triggering a public comment period. Biopharmaceutical companies with existing or planned deals in China are advised to review their portfolios and assess potential compliance risks. The rule underscores the growing geopolitical tensions and their impact on global drug development. This listing links straight to the original page, where the content is available in full.